Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression
We report a 66-year-old Japanese male with end-stage renal disease (ESRD) and advanced non-small cell lung cancer (NSCLC) who was on hemodialysis. The patient harbored high programmed death ligand 1 (PD-L1) expression and was successfully treated with pembrolizumab. Laboratory examination upon diagn...
Gespeichert in:
| Veröffentlicht in: | Respiratory investigation 2018-07, Vol.56 (4), p.361-364 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 364 |
|---|---|
| container_issue | 4 |
| container_start_page | 361 |
| container_title | Respiratory investigation |
| container_volume | 56 |
| creator | Ishizuka, Shiho Sakata, Shinya Yoshida, Chieko Takaki, Akira Saeki, Sho Nakamura, Kazuyoshi Fujii, Kazuhiko |
| description | We report a 66-year-old Japanese male with end-stage renal disease (ESRD) and advanced non-small cell lung cancer (NSCLC) who was on hemodialysis. The patient harbored high programmed death ligand 1 (PD-L1) expression and was successfully treated with pembrolizumab. Laboratory examination upon diagnosis showed elevated serum creatinine (6.58 mg/dL). We administered pembrolizumab (200 mg/body) and repeated every 3 weeks. His renal dysfunction gradually progressed, hemodialysis was initiated after eight courses of pembrolizumab, and the antitumor effect was maintained at five months after hemodialysis initiation. Therefore, pembrolizumab can be administered for patients with ESRD and advanced NSCLC, who harbor high PD-L1 expression, during preparation for hemodialysis. |
| doi_str_mv | 10.1016/j.resinv.2018.03.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2039916351</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2212534518300467</els_id><sourcerecordid>2039916351</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-1967eaf3426999f4470acaa8f1a34debc1a1b6dbb54864695813ef19e72f94ba3</originalsourceid><addsrcrecordid>eNp9UU1v1TAQjBAVrdr-A4R85JLUX3HiCxIqlCI9CSTgbG2czXt-SpxgJ4-Wn8EvxlFKj_hgrzSzO96ZLHvNaMEoUzfHImB0_lRwyuqCioLS8kV2wTnjeSlK8fK5luV5dh3jkaajSi6ZepWdc10pWZX8IvvzbbEWY-yWnswBYR7Qz6R5JBMOTRh793sZoCHOEyATzG5Ff7n5QNC3eZxhjySgh560LiJE3EBoT-AttsSPPo8D9D2xmK5-8XtiVygQ8C05uP2BfP2Q7xjBhymtFN3or7KzDvqI10_vZfbj7uP32_t89-XT59v3u9yKWs0506pC6ITkSmvdSVlRsAB1x0DIFhvLgDWqbZpS1koqXdZMYMc0VrzTsgFxmb3d5k5h_LlgnM3g4vpN8Dgu0XAqtGZKlCxR5Ua1YYwxYGem4AYIj4ZRswZijmYLxKyBGCpMCiS1vXlSWJoB2-emf_YnwruNgGnPk8Ngok0WJ-dcQDubdnT_V_gLI4egWQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2039916351</pqid></control><display><type>article</type><title>Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ishizuka, Shiho ; Sakata, Shinya ; Yoshida, Chieko ; Takaki, Akira ; Saeki, Sho ; Nakamura, Kazuyoshi ; Fujii, Kazuhiko</creator><creatorcontrib>Ishizuka, Shiho ; Sakata, Shinya ; Yoshida, Chieko ; Takaki, Akira ; Saeki, Sho ; Nakamura, Kazuyoshi ; Fujii, Kazuhiko</creatorcontrib><description>We report a 66-year-old Japanese male with end-stage renal disease (ESRD) and advanced non-small cell lung cancer (NSCLC) who was on hemodialysis. The patient harbored high programmed death ligand 1 (PD-L1) expression and was successfully treated with pembrolizumab. Laboratory examination upon diagnosis showed elevated serum creatinine (6.58 mg/dL). We administered pembrolizumab (200 mg/body) and repeated every 3 weeks. His renal dysfunction gradually progressed, hemodialysis was initiated after eight courses of pembrolizumab, and the antitumor effect was maintained at five months after hemodialysis initiation. Therefore, pembrolizumab can be administered for patients with ESRD and advanced NSCLC, who harbor high PD-L1 expression, during preparation for hemodialysis.</description><identifier>ISSN: 2212-5345</identifier><identifier>EISSN: 2212-5353</identifier><identifier>DOI: 10.1016/j.resinv.2018.03.005</identifier><identifier>PMID: 29764752</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Aged ; Anti-PD-1-antibody ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antineoplastic Agents, Immunological - administration & dosage ; B7-H1 Antigen - genetics ; B7-H1 Antigen - metabolism ; Carcinoma, Non-Small-Cell Lung - complications ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Chronic renal failure ; End-stage renal disease ; Gene Expression ; Hemodialysis ; Humans ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - therapy ; Lung Neoplasms - complications ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Male ; Neoplasm Staging ; Pembrolizumab ; Renal Dialysis ; Treatment Outcome</subject><ispartof>Respiratory investigation, 2018-07, Vol.56 (4), p.361-364</ispartof><rights>2018 The Japanese Respiratory Society</rights><rights>Copyright © 2018 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-1967eaf3426999f4470acaa8f1a34debc1a1b6dbb54864695813ef19e72f94ba3</citedby><cites>FETCH-LOGICAL-c386t-1967eaf3426999f4470acaa8f1a34debc1a1b6dbb54864695813ef19e72f94ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29764752$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ishizuka, Shiho</creatorcontrib><creatorcontrib>Sakata, Shinya</creatorcontrib><creatorcontrib>Yoshida, Chieko</creatorcontrib><creatorcontrib>Takaki, Akira</creatorcontrib><creatorcontrib>Saeki, Sho</creatorcontrib><creatorcontrib>Nakamura, Kazuyoshi</creatorcontrib><creatorcontrib>Fujii, Kazuhiko</creatorcontrib><title>Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression</title><title>Respiratory investigation</title><addtitle>Respir Investig</addtitle><description>We report a 66-year-old Japanese male with end-stage renal disease (ESRD) and advanced non-small cell lung cancer (NSCLC) who was on hemodialysis. The patient harbored high programmed death ligand 1 (PD-L1) expression and was successfully treated with pembrolizumab. Laboratory examination upon diagnosis showed elevated serum creatinine (6.58 mg/dL). We administered pembrolizumab (200 mg/body) and repeated every 3 weeks. His renal dysfunction gradually progressed, hemodialysis was initiated after eight courses of pembrolizumab, and the antitumor effect was maintained at five months after hemodialysis initiation. Therefore, pembrolizumab can be administered for patients with ESRD and advanced NSCLC, who harbor high PD-L1 expression, during preparation for hemodialysis.</description><subject>Aged</subject><subject>Anti-PD-1-antibody</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antineoplastic Agents, Immunological - administration & dosage</subject><subject>B7-H1 Antigen - genetics</subject><subject>B7-H1 Antigen - metabolism</subject><subject>Carcinoma, Non-Small-Cell Lung - complications</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Chronic renal failure</subject><subject>End-stage renal disease</subject><subject>Gene Expression</subject><subject>Hemodialysis</subject><subject>Humans</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Lung Neoplasms - complications</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Male</subject><subject>Neoplasm Staging</subject><subject>Pembrolizumab</subject><subject>Renal Dialysis</subject><subject>Treatment Outcome</subject><issn>2212-5345</issn><issn>2212-5353</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1v1TAQjBAVrdr-A4R85JLUX3HiCxIqlCI9CSTgbG2czXt-SpxgJ4-Wn8EvxlFKj_hgrzSzO96ZLHvNaMEoUzfHImB0_lRwyuqCioLS8kV2wTnjeSlK8fK5luV5dh3jkaajSi6ZepWdc10pWZX8IvvzbbEWY-yWnswBYR7Qz6R5JBMOTRh793sZoCHOEyATzG5Ff7n5QNC3eZxhjySgh560LiJE3EBoT-AttsSPPo8D9D2xmK5-8XtiVygQ8C05uP2BfP2Q7xjBhymtFN3or7KzDvqI10_vZfbj7uP32_t89-XT59v3u9yKWs0506pC6ITkSmvdSVlRsAB1x0DIFhvLgDWqbZpS1koqXdZMYMc0VrzTsgFxmb3d5k5h_LlgnM3g4vpN8Dgu0XAqtGZKlCxR5Ua1YYwxYGem4AYIj4ZRswZijmYLxKyBGCpMCiS1vXlSWJoB2-emf_YnwruNgGnPk8Ngok0WJ-dcQDubdnT_V_gLI4egWQ</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Ishizuka, Shiho</creator><creator>Sakata, Shinya</creator><creator>Yoshida, Chieko</creator><creator>Takaki, Akira</creator><creator>Saeki, Sho</creator><creator>Nakamura, Kazuyoshi</creator><creator>Fujii, Kazuhiko</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201807</creationdate><title>Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression</title><author>Ishizuka, Shiho ; Sakata, Shinya ; Yoshida, Chieko ; Takaki, Akira ; Saeki, Sho ; Nakamura, Kazuyoshi ; Fujii, Kazuhiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-1967eaf3426999f4470acaa8f1a34debc1a1b6dbb54864695813ef19e72f94ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Anti-PD-1-antibody</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antineoplastic Agents, Immunological - administration & dosage</topic><topic>B7-H1 Antigen - genetics</topic><topic>B7-H1 Antigen - metabolism</topic><topic>Carcinoma, Non-Small-Cell Lung - complications</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Chronic renal failure</topic><topic>End-stage renal disease</topic><topic>Gene Expression</topic><topic>Hemodialysis</topic><topic>Humans</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Lung Neoplasms - complications</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Male</topic><topic>Neoplasm Staging</topic><topic>Pembrolizumab</topic><topic>Renal Dialysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ishizuka, Shiho</creatorcontrib><creatorcontrib>Sakata, Shinya</creatorcontrib><creatorcontrib>Yoshida, Chieko</creatorcontrib><creatorcontrib>Takaki, Akira</creatorcontrib><creatorcontrib>Saeki, Sho</creatorcontrib><creatorcontrib>Nakamura, Kazuyoshi</creatorcontrib><creatorcontrib>Fujii, Kazuhiko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Respiratory investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ishizuka, Shiho</au><au>Sakata, Shinya</au><au>Yoshida, Chieko</au><au>Takaki, Akira</au><au>Saeki, Sho</au><au>Nakamura, Kazuyoshi</au><au>Fujii, Kazuhiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression</atitle><jtitle>Respiratory investigation</jtitle><addtitle>Respir Investig</addtitle><date>2018-07</date><risdate>2018</risdate><volume>56</volume><issue>4</issue><spage>361</spage><epage>364</epage><pages>361-364</pages><issn>2212-5345</issn><eissn>2212-5353</eissn><abstract>We report a 66-year-old Japanese male with end-stage renal disease (ESRD) and advanced non-small cell lung cancer (NSCLC) who was on hemodialysis. The patient harbored high programmed death ligand 1 (PD-L1) expression and was successfully treated with pembrolizumab. Laboratory examination upon diagnosis showed elevated serum creatinine (6.58 mg/dL). We administered pembrolizumab (200 mg/body) and repeated every 3 weeks. His renal dysfunction gradually progressed, hemodialysis was initiated after eight courses of pembrolizumab, and the antitumor effect was maintained at five months after hemodialysis initiation. Therefore, pembrolizumab can be administered for patients with ESRD and advanced NSCLC, who harbor high PD-L1 expression, during preparation for hemodialysis.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>29764752</pmid><doi>10.1016/j.resinv.2018.03.005</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2212-5345 |
| ispartof | Respiratory investigation, 2018-07, Vol.56 (4), p.361-364 |
| issn | 2212-5345 2212-5353 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2039916351 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Aged Anti-PD-1-antibody Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Agents, Immunological - administration & dosage B7-H1 Antigen - genetics B7-H1 Antigen - metabolism Carcinoma, Non-Small-Cell Lung - complications Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Chronic renal failure End-stage renal disease Gene Expression Hemodialysis Humans Kidney Failure, Chronic - complications Kidney Failure, Chronic - therapy Lung Neoplasms - complications Lung Neoplasms - drug therapy Lung Neoplasms - genetics Male Neoplasm Staging Pembrolizumab Renal Dialysis Treatment Outcome |
| title | Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T15%3A39%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Successful%20treatment%20by%20pembrolizumab%20in%20a%20patient%20with%20end-stage%20renal%20disease%20with%20advanced%20non-small%20cell%20lung%20cancer%20and%20high%20PD-L1%20expression&rft.jtitle=Respiratory%20investigation&rft.au=Ishizuka,%20Shiho&rft.date=2018-07&rft.volume=56&rft.issue=4&rft.spage=361&rft.epage=364&rft.pages=361-364&rft.issn=2212-5345&rft.eissn=2212-5353&rft_id=info:doi/10.1016/j.resinv.2018.03.005&rft_dat=%3Cproquest_cross%3E2039916351%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2039916351&rft_id=info:pmid/29764752&rft_els_id=S2212534518300467&rfr_iscdi=true |